Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis

The cutaneous microbiome is increasingly recognized as a contributor to skin diseases like atopic dermatitis (AD) and psoriasis. Although traditionally AD and psoriasis have been viewed as having opposing immunologic findings, recent evidence suggests an overlap in ceramide-family lipid production i...

Full description

Bibliographic Details
Main Authors: Portia Gough, Jordan Zeldin, Ian A. Myles
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094376/full
_version_ 1798004274069766144
author Portia Gough
Jordan Zeldin
Ian A. Myles
author_facet Portia Gough
Jordan Zeldin
Ian A. Myles
author_sort Portia Gough
collection DOAJ
description The cutaneous microbiome is increasingly recognized as a contributor to skin diseases like atopic dermatitis (AD) and psoriasis. Although traditionally AD and psoriasis have been viewed as having opposing immunologic findings, recent evidence suggests an overlap in ceramide-family lipid production in the protection against symptoms. We recently identified that specific environmental pollutants may drive dysbiosis through direct suppression of ceramide-family lipids produced by health-associated skin bacteria in atopic dermatitis (AD). We further demonstrated that one such bacteria, Roseomonas mucosa, generated significant clinical improvement in AD lasting beyond active treatment via lipid-mediated modulation of tumor necrosis factor (TNF) signaling. To assess the potential preclinical benefit of R. mucosa in psoriasis we assessed for direct effects on surface TNF signaling in cell cultures and identified direct effects on the TNF axis. We also identified preclinical efficacy of R. mucosa treatment in the imiquimod mouse model of psoriasis. Finally, we expanded our previous environmental assessment for psoriasis to include more traditional markers of air quality and found a strong association between disease rates and ambient carbon monoxide (CO), nitrogen dioxide (NO2), and particulate matter (PM). At the current stage this work is speculative but does support consideration of further preclinical models and/or clinical assessments to evaluate any potential for therapeutic benefit through microbial manipulation and/or environmental mitigation.
first_indexed 2024-04-11T12:21:04Z
format Article
id doaj.art-007fdd3a9119466aaccffc2afa1a2fb8
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-11T12:21:04Z
publishDate 2022-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-007fdd3a9119466aaccffc2afa1a2fb82022-12-22T04:24:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.10943761094376Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasisPortia GoughJordan ZeldinIan A. MylesThe cutaneous microbiome is increasingly recognized as a contributor to skin diseases like atopic dermatitis (AD) and psoriasis. Although traditionally AD and psoriasis have been viewed as having opposing immunologic findings, recent evidence suggests an overlap in ceramide-family lipid production in the protection against symptoms. We recently identified that specific environmental pollutants may drive dysbiosis through direct suppression of ceramide-family lipids produced by health-associated skin bacteria in atopic dermatitis (AD). We further demonstrated that one such bacteria, Roseomonas mucosa, generated significant clinical improvement in AD lasting beyond active treatment via lipid-mediated modulation of tumor necrosis factor (TNF) signaling. To assess the potential preclinical benefit of R. mucosa in psoriasis we assessed for direct effects on surface TNF signaling in cell cultures and identified direct effects on the TNF axis. We also identified preclinical efficacy of R. mucosa treatment in the imiquimod mouse model of psoriasis. Finally, we expanded our previous environmental assessment for psoriasis to include more traditional markers of air quality and found a strong association between disease rates and ambient carbon monoxide (CO), nitrogen dioxide (NO2), and particulate matter (PM). At the current stage this work is speculative but does support consideration of further preclinical models and/or clinical assessments to evaluate any potential for therapeutic benefit through microbial manipulation and/or environmental mitigation.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094376/fullpsoriasismicrobiomeRoseomonasatopic dermatatispollution
spellingShingle Portia Gough
Jordan Zeldin
Ian A. Myles
Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
Frontiers in Immunology
psoriasis
microbiome
Roseomonas
atopic dermatatis
pollution
title Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
title_full Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
title_fullStr Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
title_full_unstemmed Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
title_short Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
title_sort assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis
topic psoriasis
microbiome
Roseomonas
atopic dermatatis
pollution
url https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094376/full
work_keys_str_mv AT portiagough assessingmicrobialmanipulationandenvironmentalpollutantsinthepathogenesisofpsoriasis
AT jordanzeldin assessingmicrobialmanipulationandenvironmentalpollutantsinthepathogenesisofpsoriasis
AT ianamyles assessingmicrobialmanipulationandenvironmentalpollutantsinthepathogenesisofpsoriasis